BioLineRx Ltd. Quarterly Research And Development Expense in USD from Q2 2017 to Q2 2024

Taxonomy & unit
ifrs-full: USD
Summary
BioLineRx Ltd. annual/quarterly Research And Development Expense history and growth rate from Q2 2017 to Q2 2024.
  • BioLineRx Ltd. Research And Development Expense for the quarter ending June 30, 2024 was $2.23M, a 26% decline year-over-year.
  • BioLineRx Ltd. annual Research And Development Expense for 2024 was $9.15M, a 26.9% decline from 2023.
  • BioLineRx Ltd. annual Research And Development Expense for 2023 was $12.5M, a 29% decline from 2022.
  • BioLineRx Ltd. annual Research And Development Expense for 2022 was $17.6M, a 9.44% decline from 2021.
Research And Development Expense, Quarterly (USD)
Research And Development Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $2.23M -$781K -26% Apr 1, 2024 Jun 30, 2024 6-K 2024-08-15
Q2 2023 $3.01M -$2.39M -44.3% Apr 1, 2023 Jun 30, 2023 6-K 2024-08-15
Q2 2022 $5.4M +$256K +4.98% Apr 1, 2022 Jun 30, 2022 6-K 2023-08-30
Q2 2021 $5.14M +$499K +10.8% Apr 1, 2021 Jun 30, 2021 6-K 2022-08-16
Q2 2020 $4.64M -$662K -12.5% Apr 1, 2020 Jun 30, 2020 6-K 2021-08-18
Q2 2019 $5.3M +$818K +18.2% Apr 1, 2019 Jun 30, 2019 6-K 2020-08-06
Q2 2018 $4.48M +$422K +10.4% Apr 1, 2018 Jun 30, 2018 6-K 2019-08-06
Q2 2017 $4.06M Apr 1, 2017 Jun 30, 2017 6-K 2018-08-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.